Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00280917 · ClinicalTrials.gov registry record · Phase 2

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

A Phase 2 study of Rheumatoid Arthritis, sponsored by Can-Fite BioPharma.

Completed
Registry status
Phase 2
Development phase
254
Enrollment target
20
Study locations

NCT00280917: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by Can-Fite BioPharma.

NCT00280917 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Can-Fite BioPharma. The registered enrollment target is 254 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00280917, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Can-Fite BioPharma.

COMPLETED
Registry status
Phase 2
Development phase
254 participants
Enrollment target
20
Study locations

Study Summary

This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.

Primary Outcome

ACR 20 response (20% improvnent in RA based on swollen and tender joint counts, physician and patient global assessments of disease activity, a patient pain score) at endpoint (Week 12), with all-cause dropouts considered as nonresponders (nonresponder imputation) in the Intent-To-Treat (ITT) population

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG CF101

Study Locations (20)

Other

  • Can-Fite Investigational Site - Plovdiv
  • Can-Fite Investigational Site - Sofia
  • Can-Fite Investigational Site - Sofia
  • Can-Fite Investigational Site - Stara Zagora
  • Can-Fite Investigational Sites - Afula
  • Can-Fite Investigational Site - Ashkelon
  • Can-Fite Investigational Site - Beer Yaakov
  • Can-Fite Investigational Site - Haifa
  • Can-Fite Investigational Site - Haifa
  • Can-Fite Investigational Site - Jerusalem
  • Can-Fite Investigational Site - Jerusalem
  • Can-Fite Investigational Site - Jerusalem
  • Can-Fite Investigational Site - Kfar Saba
  • Can-Fite Investigational Site - Tel Litwinsky
  • Can-Fite Investigational Site - Bialystok

Ohio

  • Can-Fite Invesitigational Site - Cleveland
  • Can-Fite Investigational Site - Perrysburg

Arizona

  • Can-Fite Investigational Site - Peoria

New York

  • Can-Fite Investigational Site - Albany

Texas

  • Can-Fite Investigational Site - Sugar Land

Trial Details

FieldValue
Enrollment Target 254 participants
Start Date 2006-06
Est. Completion 2007-04
Phase Phase 2
Can-Fite BioPharma

4 total trials

What the finished NCT00280917 record still lists

NCT00280917 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which CF101 is the first listed.

NCT00280917 names 20 study sites across 5 states, led by Other, Ohio, Arizona.

Frequently Asked Questions

What is clinical trial NCT00280917 about?

NCT00280917 is a clinical study titled "Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients". This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.

What is the current status of trial NCT00280917?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2006-06. Estimated completion is 2007-04.

What conditions does trial NCT00280917 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00280917?

The interventions under investigation include: CF101 (DRUG).

Who is sponsoring clinical trial NCT00280917?

This trial is sponsored by Can-Fite BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00280917 being conducted?

This trial has 20 study locations across Arizona, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00280917's enrollment target sits among peer trials

254 73rd of 197 higher than 125 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04390737 · 254 participants · Phase 1

    Evaluate the Safety and Clinical Activity of HH2853

  • NCT04677647 · 254 participants · NA

    OurChild: A Health IT Solution to Reduce Minority Health Disparities

  • NCT05503797 · 254 participants · Phase 2

    A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • NCT06167317 · 254 participants · Phase 1

    Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00280917, the US trial registry maintained by the National Library of Medicine. NCT00280917 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.